The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …

Standard first-line chemotherapy results in disease progression and death within one year in
most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …

Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment …

Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-
line platinum-based chemotherapy are robust, but responses lack durability. CheckMate …

Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …